Hester Biosciences Share Price Surges Over 5%; Approves Divestment of 43.81% Stake in Texas Lifesciences

Hester Biosciences Limited has approved the divestment of part of its shareholding in Texas Lifesciences Private Limited (TLPL), as per an exchange filing. The decision was taken at a board meeting held on 11 March 2026, following recommendations from the company’s audit committee.  

Proposed Stake Sale to Reduce Holding to 11% 

Under the approved plan, the company will sell 43.81% equity shareholding in TLPL from its existing 54.81% stake. Once the transaction is completed, Hester Biosciences’ holding in the company will reduce to 11%, and TLPL will no longer remain its subsidiary.  

Share Transfer Arrangement 

The shares will be transferred to Ticop Life Private Limited, an entity affiliated with the existing promoter shareholders of Texas Lifesciences. The agreement for the sale was signed on 5 March 2026.  

The total value of the transaction has been set at ₹92 million, subject to the terms and conditions outlined in the agreement. The company expects the share transfer process to be completed within 3 months from the date of the agreement.  

Financial Profile of the Subsidiary 

Texas Lifesciences reported turnover of ₹285.89 million and a net worth of ₹134.17 million for the financial year 2024-25.  

The company’s disclosure also noted that more than 97% of TLPL’s sales were made to Hester Biosciences Limited. These transactions are eliminated when the group prepares its consolidated financial statements.  

Regulatory and Transaction Details 

The company clarified that the transaction does not qualify as a related-party transaction. According to the disclosure, the parties involved in the sale, Hester Biosciences and Ticop Life Private Limited are not related entities.  

The sale is also not part of any scheme of arrangement, and the disclosure was made through an exchnage filing dated march 11, 2026. 

Read More: 

Hester Biosciences Share Price Performance  

As of March 11, 2026, 11:35 am, Hester Biosciences share price was trading at ₹1,544.90, over 5% increase from the previous closing price. 

Conclusion 

Following the completion of the share transfer, Texas Lifesciences will cease to be a subsidiary of Hester Biosciences. The company, however, will continue to hold a minority stake of 11% and maintain business dealings with the entity. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.